-
ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast CancerDaiichi Sankyo2023-11-10 06:54:59ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive
-
Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCSDaiichi Sankyo2023-11-10 06:54:38Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS
-
Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data presented at AHA 2020Daiichi Sankyo2020-11-16 10:51:13Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data
-
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with CancerDaiichi Sankyo2020-11-11 20:09:14Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization
-
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant TherapyDaiichi Sankyo2023-11-09 21:02:38DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive
-
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:02:11ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T CellsDaiichi Sankyo2023-11-09 21:01:48Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated
-
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:01:36ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020Daiichi Sankyo2023-11-09 21:01:17Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with
-
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal CancerDaiichi Sankyo2020-09-15 15:08:35Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced
